Navigation Links
Children's Memorial Research Center, Chicago Becomes a Member of GeneGo's MetaMiner Stem Cell Partnership Program
Date:4/14/2009

ST. JOSEPH, Mich., April 14 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Professor Marcelo Bento Soares of Children's Memorial Research Center has joined the MetaMiner Stem Cell Partnership Program. The goal of the program is to develop a series of blueprint pathway maps for adult, embryonic, fetal, fibroblasts, hematopoietic, mesenchymal, multipotent, neoplastic, pluripotent and totipotent stem cells.

"We feel that it is important to support such an initiative as there is a lot of stem cell information in the literature but no one has brought it all together in a set of comprehensive pathway maps," said Professor Marcelo Bento Soares, Director, Cancer Biology and Epigenomics Program. "This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly."

"We had our kick off meeting last month and it went very well; we have a lot of other companies and academic groups that want to join this important project as this will be the first stem cell pathway platform for researchers to advance science. Stem cell research is attracting a lot of attention at the moment," said Julie Bryant, GeneGo's VP of Business Development. "We have a lot of experience in building pathway maps and we plan to have 10 types of stem cell drug centric pathway maps completed in 24 months."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

About Children's Memorial Research Center

The mission of Children's Memorial Research Center is to generate new knowledge leading to advancements in the prevention, diagnosis, and treatment of diseases that affect the development of children through adolescence as well as adult disorders that derive from them. Our multidisciplinary teams of physicians, scientists, technicians, nurses and trainees are committed to making discoveries that will improve the lives of children and their families.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
2. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
3. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
4. Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell
5. Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund
6. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
7. Memorial Medical First in Stanislaus County to Provide Convertible Ultrasound From ZONARE
8. New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague
9. Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market
10. ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
11. Researchers develop new way to see single RNA molecules inside living cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)...  VWR Corporation (NASDAQ: VWR), the leading global independent provider ... today reported its financial results for the fourth quarter and ... 4Q16 record quarterly net sales of $1.13 ... basis. 4Q16 EMEA-APAC segment net ... the Americas net sales increased 2.5%, or down 0.9% on ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, ...
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill ... a strange place for a head lice treatment salon to ... between a Tuscan restaurant and a French bistro on E ... perfect. "We aren,t just any old lice clinic, we pride ... feel comfortable, and release some of the stigma associated with ...
(Date:2/23/2017)... ... February 23, 2017 , ... David ... Inventors Recognition Reception at Purdue Research Park of West Lafayette, Indiana. ... recognition of outstanding contributions to, and success with, commercializing discoveries from Purdue research. ...
Breaking Biology Technology:
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
(Date:2/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the LEERINK Partners 6th Annual Global Healthcare ... Wednesday, February 15, 2017 at 10 a.m. Eastern Time. ... can be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)...   TapImmune, Inc. (NASDAQ: ... the development of innovative peptide and gene-based immunotherapeutics ... metastatic disease, announced today it has successfully completed ... second clinical lot of TPIV 200, the company,s ... manufactured vaccine product will be used to supply ...
Breaking Biology News(10 mins):